Ranbaxy on a roll with generic Lipitor in Europe and Australia
This article was originally published in Scrip
Ranbaxy Laboratories continues to roll out its generic version of Pfizer's cholesterol lowering drug Lipitor (atorvastatin) in international markets, the latest being Germany, Italy, Sweden and the Netherlands. Ranbaxy, part of Daiichi Sankyo, last month also launched generic atorvastatin in Australia with three months' exclusivity, and has reported gains in market share in the US.
You may also be interested in...
Wockhardt has received approvals in India for two novel broad spectrum antibiotics with "advantageous" safety features over older MRSA drugs and the firm hopes to take them to other emerging markets as well, with China on the radar.
2019 saw Indian companies advance innovation efforts and build and expand their specialty portfolios and biosimilars businesses. But manufacturing compliance issues weighed down several firms while on another front charges against the Singh brothers of Ranbaxy escalated.
Glenmark is working on a combination of remogliflozin and teneligliptin in India, which if successful could bring additional sting to its portfolio in the country's bustling diabetes segment. But Boehringer-Lilly’s rival Glyxambi already has a head-start.